SGLT2 Inhibitors and Mechanisms of Hypertension
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Purpose of review We sought to review currently available data on the safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 2 diabetes mellitus patients with hypertension.Recent findings Inhibition of SGLT2 in the renal proximal tubule results in increased urinary glucose excretion and modest improvements of hemoglobin A1C. Treatment with any of the three currently FDA-approved SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin) results in sustained systolic and diastolic blood pressure reduction, in part via minimal natriuresis and possible reductions in sympathetic tone. Recent randomized clinical trials in high cardiovascular risk patients with type 2 diabetes suggest that the unique effects of SGLT2 inhibitors on blood pressure and body weight may translate into reduced cardiovascular events and slowed kidney disease progression. However, concerns about volume depletion and acute kidney injury have been raised. SGLT2 inhibitors are viable second-line glucose-lowering agents for people with type 2 diabetes with high cardiovascular risk.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SGLT2 inhibitors significantly lower systolic and diastolic blood pressure without reflex activation of the sympathetic nervous system and are even able to change the non-dipping to dipping circadian blood pressure profile.”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [114]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Cruickshank, K., Riste, L., Anderson, S. G., Wright, J. S., Dunn, G., & Gosling, R. G. (2002) · Circulation · doi:10.1161/01.cir.0000033824.02722.f7 · Cited by 1,531
Biology of Human Sodium Glucose Transporters
Wright, E. M., Loo, D. D. F., & Hirayama, B. A. (2011) · Physiological Reviews · doi:10.1152/physrev.00055.2009 · Cited by 1,430
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2260 · Cited by 867
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837
Cited by
Neuroprotective effect of SGLT2 inhibitors.
Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P. (2021) · Molecules · doi:10.3390/molecules26237213 · Cited by 304
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
Scheen, A. J. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0392-2 · Cited by 267
SGLT2 Inhibitor–Induced Sympathoinhibition
Herat, L. Y., Magno, A. L., Rudnicka, C., Hricova, J., Carnagarin, R., Ward, N. C., Arcambal, A., Kiuchi, M. G., Head, G. A., Schlaich, M. P., et al. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.11.007 · Cited by 233
“Type 2 diabetes and hypertension frequently coexist (6) and hypertension is a risk factor for chronic kidney and cardiovascular disease.”
BackgroundAn update on the safety of SGLT2 inhibitors
Scheen, A. J. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1602116 · Cited by 174
“However, scattered reports suggested that there might be a risk for AKI with the use of SGLT2is, which occasionally might require renal replacement therapy [41,42].”
BackgroundEffect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure
Scheen, A. J. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1165-1 · Cited by 122
Metadata
- Authors
- Briasoulis, A., Al Dhaybi, O., & Bakris, G. L.
- Affiliations
- University of Chicago (US)
- Corresponding author
- Bakris, George L.
- ORCID
- Bakris, George L.
- Venue
- Current Cardiology Reports
- Published
- 2018-01
- Volume
- 20
- Issue
- 1
- Pages
- 1-1
- ISSN
- 1523-3782 (ISSN-L)
- 1534-3170
- OpenAlex
- W2785530117
- Cited by
- 94
- References
- 56
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 11 · 2023: 9 · 2022: 11 · 2021: 15 · 2020: 17 · 2019: 14 · 2018: 5
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Current Cardiology Reports (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- SGLT2 inhibitors, hypertension, type 2 diabetes, blood pressure reduction, sodium excretion, sympathetic tone, acute kidney injury, hypovolemia, cardiovascular risk, kidney disease progression, canagliflozin, dapagliflozin, empagliflozin, urinary glucose excretion, body weight
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Blood Pressure, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Glycated Hemoglobin, Humans, Hypertension, Hypoglycemic Agents, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SGLT2 Inhibitors and Mechanisms of Hypertension. https://app.cochat.ai/papers/10.1007/s11886-018-0943-5
- The paper
- Briasoulis, A., Al Dhaybi, O., & Bakris, G. L. (2018). SGLT2 Inhibitors and Mechanisms of Hypertension. Current Cardiology Reports. https://doi.org/10.1007/s11886-018-0943-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.